Last reviewed · How we verify
NCT06758375
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
Phase 2 trial testing Low-dose teclistamab in Multiple Myeloma, Newly Diagnosed in 10 participants. Currently enrolling.
7 September 2026
Quick facts
| Lead sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 3 March 2025 |
| Primary completion | 7 September 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Low-dose teclistamab — full drug profile →
Conditions studied
- Multiple Myeloma, Newly Diagnosed — all drugs for Multiple Myeloma, Newly Diagnosed →
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Who can join
18 and older, any sex, with Multiple Myeloma, Newly Diagnosed. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.
Shastri T, Trabolsi A, Arumov A, Schatz JH. · · 2025 · cited 4× · PMID 40751114 · DOI 10.1007/s40259-025-00735-z
Verify or expand the search:
- PubMed search for NCT06758375
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma, Newly Diagnosed
Currently open trials in the same condition.
- NCT07106736 — MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma · Phase 2 · recruiting
- NCT07106710 — ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma · Phase 2 · recruiting
Other Hospital Universitario Dr. Jose E. Gonzalez trials
Trials by the same sponsor.
- NCT07401992 — Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis · Phase 4 · recruiting
- NCT06904599 — Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment · Phase 2 · recruiting
- NCT07039877 — Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients · Phase 2 · recruiting
- NCT06209190 — Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation · NA · completed
- NCT06348602 — Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSC · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06758375 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Dr. Jose E. Gonzalez
- Last refreshed: 20 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06758375.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing